Research highlights from the 2018 European Respiratory Society International Congress: airway disease.

[en] The annual European Respiratory Society (ERS) International Congress (held in Paris in 2018) was once again a platform for discussion of the highest-quality scientific research, cutting-edge techniques and innovative new therapies within the respiratory field. This article discusses only some of the high-quality research studies presented at this year's Congress, with a particular focus on airway diseases including asthma, chronic obstructive pulmonary disease (COPD), bronchiectasis and cough, as presented through Assembly 5 of the ERS (Airway Diseases: Asthma and COPD). The authors establish the key take-home messages of these studies, compare their findings and place them in the context of current understanding.

Disciplines :

Cardiovascular & respiratory systems

Author, co-author :

SCHLEICH, FLorence ; Centre Hospitalier Universitaire de Liège - CHU > Département de médecine interne > Service de pneumologie - allergologie

Bikov, Andras

Mathioudakis, Alexander G.

McDonnell, Melissa

Andersson, Cecilia

Bonini, Matteo

Uller, Lena

Idzko, Marco

Singh, Dave

Lopez-Campos, Jose Luis

More authors (5 more)

Language :

English

Title :

Research highlights from the 2018 European Respiratory Society International Congress: airway disease.

Publication date :

2019

Journal title :

ERJ Open Research

eISSN :

2312-0541

Publisher :

European Respiratory Society, Sheffield, United Kingdom

Volume :

Issue :

Peer reviewed :

Peer Reviewed verified by ORBi

Additional URL :

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6421359/

Available on ORBi :

since 26 May 2020

Statistics

Number of views

49 (3 by ULiège)

Number of downloads

34 (3 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

OpenCitations

Bibliography

World Health Organization. Chronic respiratory diseases: asthma. www.who.int/respiratory/asthma/en/.
Pavord ID, Bush A, Holgate S. Asthma diagnosis: addressing the challenges. Lancet Respir Med 2015; 3: 339-341.
Wenzel SE. Asthma: defining of the persistent adult phenotypes. Lancet 2006; 368: 804-813.
Nawijn M, Carpaij O, Viera Braga F, et al. Novel cell types and altered cell states in asthma revealed by single-cell RNA sequencing of airway wall biopsies. Eur Respir J 2018; 52: Suppl. 62, OA505.
Tokunaga Y, Imaoka H, Morimatsu Y, et al. Role of CD63 in human fatal asthma and murine asthma model. Eur Respir J 2018; 52: Suppl. 62, PA648.
Silberbrandt A, Vin Bulow A, Backer V, et al. Airway eosinophilia in severe asthma is associated with smoking history. Eur Respir J 2018; 52: Suppl. 62, PA948.
Mistry H, Freeman A, Thirwall Y, et al. Does the nature of adult difficult asthma differ by age of onset? Findings from WATCH. Eur Respir J 2018; 52: Suppl. 62, PA1086.
Mathieu E, Escribano-Vazquez U, Descamps D, et al. Paradigms of lung microbiota functions in health and disease, particularly, in asthma. Front Physiol 2018; 9: 1168.
Potaczek DP, Harb H, Alhamwe BA, et al. Interleukin-6 is important for the development of Acinetobacter lwoffii-mediated protection against asthma. Eur Respir J 2018; 52: Suppl. 62, PA1108.
Anatriello E, Britto A, Albertina R, et al. Lactobacillus bulgaricus reduces the expression of Toll-like 4 receptor on dendritic cells and attenuates the airway inflammation in asthmatic mice. Eur Respir J 2018; 52: Suppl. 62, PA1107.
De Boer GM, Braunstahl GJ, Hendriks RW, et al. Bacterial lysates in the prevention of asthma exacerbations in uncontrolled asthma: the Breathe study. Eur Respir J 2018; 52: Suppl. 62, PA5008.
Chapman KR, Boulet LP, Rea RM, et al. Suboptimal asthma control: prevalence, detection and consequences in general practice. Eur Respir J 2008; 31: 320-325.
van der Meer A, De Jong K, Bel EH, et al. Dynamic hyperinflation predicts impaired daily life activity in asthma. Eur Respir J 2018; 52: Suppl. 62, PA4001.
Backman H, Hedman L, Stridsman C, et al. Eosinophilic inflammation and lung function decline in a long-term follow-up of a large population-based asthma cohort. Eur Respir J 2018; 52: Suppl. 62, OA294.
Graff S, Moermans C, Louis R, et al. Impact of eosinophilia and time on lung function decline in adult asthma. Eur Respir J 2018; 52: Suppl. 62, PA2017.
Gamble J, Stevenson M, McClean E, et al. The prevalence of nonadherence in difficult asthma. Am J Respir Crit Care Med 2009; 180: 817-822.
Alahmadi F, Simpson A, Gomez C, et al. Measures of adherence in patients with severe asthma prescribed systemic steroids in the U-BIOPRED cohort. Eur Respir J 2018; 52: Suppl. 62, PA3992.
Azim A, Mistry H, Harvey MA, et al. Comorbidities in the difficult asthma clinic: results from WATCH. Eur Respir J 2018; 52: Suppl. 62, PA1087.
McDonald VM, Hiles SA, Godbout K, et al. Treatable traits can be identified in a severe asthma registry and predict future exacerbations. Respirology 2019; 24: 37-47.
Chen E, Miller GE. Stress and inflammation in exacerbations of asthma. Brain Behav Immun 2007; 21: 993-999.
Bacon S, Plourde A, Paine N, et al. Impact of acute active and passive stress on physiological responses in adults with asthma. Eur Respir J 2018; 52: Suppl. 62, PA654.
Green RH, Brightling CE, Woltmann G, et al. Analysis of induced sputum in adults with asthma: identification of subgroup with isolated sputum neutrophilia and poor response to inhaled corticosteroids. Thorax 2002; 57:875-879.
Marcon A, Marchetti P, Anto JM, et al. Inhaled corticosteroids and FEV1 decline in asthma: an international cohort study. Eur Respir J 2018; 52: Suppl. 62, OA295.
de Marco R, Marcon A, Jarvis D, et al. Inhaled steroids are associated with reduced lung function decline in subjects with asthma with elevated total IgE. J Allergy Clin Immunol 2007; 119: 611-617.
Hanania N, Fang J, Wei Z, et al. Real-world effectiveness of omalizumab in allergic asthma patients with low or high blood eosinophils: a retrospective claims analysis study. Eur Respir J 2018; 52: Suppl. 62, PA1029.
Ortega H, Meyer E, Brusselle G, et al. Immunogenicity of mepolizumab in patients with severe eosinophilic asthma: experience from the clinical development program. Eur Respir J 2018; 52: Suppl. 62, OA1650.
Wenzel S, Brusselle G, Hirsch I, et al. Benralizumab efficacy in patients with uncontrolled eosinophilic asthma by age at diagnosis. Eur Respir J 2018; 52: Suppl. 62, PA603.
Corren J, Castro M, Maspero JF. Dupilumab improves asthma-related patient reported outcomes in asthma patients with chronic rhinosinusitis or nasal polyposis (CRS/NP) in LIBERTY ASTHMA QUEST. Eur Respir J 2018; 52: Suppl. 62, PA1124.
Torrego A, Herth F, Munoz AM, et al. Bronchial thermoplasty global registry: one year results. Eur Respir J 2018; 52: Suppl. 62, OA1921.
Frix A, Heinen V, Schleich F, et al. Bronchial thermoplasty in severe asthmatics: a retrospective study on 10 cases with one year follow-up. Eur Respir J 2018; 52: Suppl. 62, PA605.
Goorsenberg AWM, D’Hooghe JNS, Slats AM, et al. The effect of bronchial thermoplasty on lung function in severe asthma patients. Eur Respir J 2018; 52: Suppl. 62, OA3560.
Sano A, Sano H, Iwanaga T, et al. The usefulness of the impulse oscillometry for predicting the treatment outcomes of bronchial thermoplasty in patients with severe asthma. Eur Respir J 2018; 52: Suppl. 62, PA3694.
Bafadhel M, Pavord ID, Russell REK. Eosinophils in COPD: just another biomarker? Lancet Respir Med 2017; 5: 747-759.
Pascoe S, Barnes N, Brusselle MT, et al. Late breaking abstract - blood eosinophil counts and treatment response in COPD: analyses of IMPACT. Eur Respir J 2018; 52: Suppl. 62, OA2127.
Burge PS, Calverley PM, Jones PW, et al. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ 2000; 320: 1297-1303.
Mathioudakis A, Foden P, Vestbo J. Late breaking abstract - blood eosinophil count (EOS) can accurately predict responsiveness to inhaled corticosteroids (ICS) in COPD, but only if measured while patients are not receiving steroids. Eur Respir J 2018; 52: Suppl. 62, OA2125.
Hurst J, Kostikos K, Chapman KR, et al. Persistent blood eosinophilia and COPD exacerbation risk after ICS withdrawal from triple therapy in the SUNSET study. Eur Respir J 2018; 52: Suppl. 62, OA5387.
Karch A, Vogelmeier C, Welte T, et al. The German COPD cohort COSYCONET: aims, methods and descriptive analysis of the study population at baseline. Respir Med 2016; 114: 27-37.
Waschki B, Alter P, Zeller T, et al. Late breaking abstract - high-sensitivity troponin I predicts all-cause mortality in stable COPD in the COSYCONET cohort. Eur Respir J 2018; 52: Suppl. 62, OA2138.
Vestbo J, Anderson W, Coxson HO, et al. Evaluation of COPD longitudinally to identify predictive surrogate end-points (ECLIPSE). Eur Respir J 2008; 31: 869-873.
Canet MRF, Noell G, Bakke P, et al. Longitudinal stability and association with all-cause mortality of the 2017 GOLD groups in the ECLIPSE cohort. Eur Resp J 2018; 52: Suppl. 62, OA2140
Prudente R, Mesquita C, Ferrari R, et al. Peripheral eosinophils and mortality in COPD patients over nine years. Eur Respir J 2018; 52: Suppl. 62, OA5383.
Jørgensen DV, Godtfredsen NS, Marsaa K, et al. Soluble urokinase plasminogen activator receptor (suPAR) predicts mortality in exacerbated COPD. Eur Respir J 2018; 52: Suppl. 62, OA2142.
Papathanassiou E, Papaioannou A, Hillas G, et al. Eosinophils and acute exacerbation of COPD: a potent biomarker for patients at increased risk. Preliminary reports. Eur Respir J 2018; 52: Suppl. 62, PA2016.
Soe AK, Kevorkova MS, Nuralieva GS, et al. Blood eosinophilia (BE) and outcomes in patients with acute sever exacerbations of COPD (AECOPD). Eur Respir J 2018; 52: Suppl. 62, OA5382.
Vogelmeier CF, Criner GJ, Martinez FJ, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease 2017 Report: GOLD executive summary. Eur Respir J 2017; 49: 1700214.
Gayle A, Dickinson S, Morris K, et al. What is the impact of GOLD 2017 recommendations in primary care? A descriptive study of patient classifications, treatment burden and costs. Int J Chron Obstruct Pulmon Dis 2018; 13: 3485-3492.
Mathioudakis AG, Vestbo J, Gayle A, et al. GOLD ABCD assessment tool: comparison of 2013 and 2017 classifications in the UK Clinical Practice Research Datalink (CPRD). Eur Respir J 2018; 52: Suppl. 62, PA2011.
Brozek G, Nowak N, Mateusz J, et al. The same COPD patients, different GOLD criteria - what are the consequences of changing GOLD 2007-2011-2017 recommendations? Eur Respir J 2018; 52: Suppl. 62, PA1164.
Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease (2019 report). Global Initiative for Chronic Obstructive Pulmonary Disease (GOLD), 2019. https://goldcopd.org/wpcontent/ uploads/2018/11/GOLD-2019-v1.7-FINAL-14Nov2018-WMS.pdf
Plutinsky M, Brat K, Koblizek V, et al. Implementation of the GOLD 2017 disease classification in a real-life COPD cohort. Eur Respir J 2018; 52: Suppl. 62, PA3858.
Chalmers JD, Aliberti S, Blasi F. Management of bronchiectasis in adults. Eur Respir J 2015; 45: 1446-1462.
Flume PA, Chalmers JD, Olivier KN. Advances in bronchiectasis: endotyping, genetics, microbiome, and disease heterogeneity. Lancet 2018; 392: 880-890.
Chalmers JD, Polverino E, Blasi F, et al. The heterogeneity of bronchiectasis patient characteristics, management and outcomes across Europe: data from the EMBARC registry. Eur Respir J 2018; 52: Suppl. 62, PA2676.
Walker P, Herrero B, Spinou A, et al. Variability in access and referral to pulmonary rehabilitation in European bronchiectasis patients enrolled in the EMBARC registry. Eur Respir J 2018; 52: Suppl. 62, OA5201.
Loebinger M, Ringshausen F, Haworth C, et al. Characteristics of patients with pulmonary non-tuberculous mycobacterial infection in bronchiectasis: data from the EMBARC registry. Eur Respir J 2018; 52: Suppl. 62, PA348.
Shoemark A, Polverino E, Blasi F, et al. Primary ciliary dyskinesia in adults with bronchiectasis: data from the Embarc registry. Eur Respir J 2018; 52: Suppl. 62, PA359.
De Soyza A, Chalmers JD, Dimakou K, et al. Impact of inflammatory bowel disease in bronchiectasis (IBD-BR) data from the EMBARC registry. Eur Respir J 2018; 52: Suppl. 62, PA2678.
McDonnell MJ, Aliberti S, Goeminne PC, et al. Comorbidities and the risk of mortality in patients with bronchiectasis: an international cohort study. Lancet Respir Med 2016; 4: 969-979.
Polverino E, Blasi F, Ringshausen F, et al. Determinants of quality of life in bronchiectasis using the quality of life bronchiectasis (QOL-B) questionnaire: data from the EMBARC registry. Eur Respir J 2018; 52: Suppl. 62, OA4951.
Heffler EM, Aliberti S, Sirena C, et al. Impact of bronchiectasis on severe asthma: data from the Severe Asthma Network Italy (SANI) registry. Eur Respir J 2018; 52: Suppl. 62, PA5494.
McDonnel MJ, Das J, O’Toole D, et al. Effects of gastro-oesophageal reflux and pulmonary micro-aspiration in bronchiectasis. Eur Respir J 2018; 52: Suppl. 62, OA4950.
Tiew PY, Aogain MM, Lim AYH, et al. Immuno-allertypes in non-cystic fibrosis bronchiectasis. Eur Respir J 2018; 52: Suppl. 62, PA1142.
Bedi P, Davidson D, McHigh B, et al. Dysregulation of lipid mediators in clinically stable bronchiectasis. Eur Respir J 2018; 52: Suppl. 62, PA2646.
Sibila Vidal O, Perea L, Cantó E, et al. Antimicrobial peptides and airway bacterial colonization in bronchiectasis. Eur Respir J 2018; 52: Suppl. 62, OA4948.
Giam YH, Shoemark A, Keir H, et al. AMPK is inhibited in severe bronchiectasis and may relate to reduced ciliary beat frequency. Eur Respir J 2018; 52: Suppl. 62, PA351.
Keir RH, Cassidy D, Crichton M, et al. Heterogeneous impact of sputum supernatant on neutrophil phagocytosis in bronchiectasis. Eur Respir J 2018; 52: Suppl. 62, OA4949.
Ramsey K, Radicioni G, Hill D, et al. Airways mucus pathogenesis in patients with non-cystic fibrosis bronchiectasis. Eur Respir J 2018; 52: Suppl. 62, PA5049.
Alcaraz Serrano V, Llorens-Llacuna J, Gimeno-Santos E, et al. Does Pseudomonas aeruginosa infection alter sputum viscoelastic properties in bronchiectasis patients? Eur Respir J 2018; 52: Suppl. 62, PA1461.
Chalmers JD, Thompson B, Froehlich J, et al. Effect of prior year pulmonary exacerbation frequency on response to ARD-3150 in patients with non-cystic fibrosis bronchiectasis chronically infected with Pseudomonas aeruginosa. Eur Respir J 2018; 52: Suppl. 62, PA2675.
Cipolla D, Davis A, Froehlich J, et al. Reduction of pulmonary exacerbations in two phase 3 trials: in-depth analyses. Eur Respir J 2018; 52: Suppl. 62, OA4954.
O’Donnell A, Gonda I, Cipolla D, et al. Open-label extension (OLE) of ORBIT-3 and ORBIT-4 trials of ARD-3150 in non-cystic fibrosis bronchiectasis (NCFB). Eur Respir J 2018; 52: Suppl. 62, PA357.
Faverio P, Bonaiti G, Zucchetti S, et al. Development of antibiotic-resistance in P. aeruginosa obtained from bronchiectasis patients: a multicentre prospective observational study. Eur Respir J 2018; 52: Suppl. 62, PA5314.
Postma DS, Brightling C, Fabbri L, et al. Unmet needs for the assessment of small airways dysfunction in asthma:introduction to the ATLANTIS study. Eur Respir J 2015; 45: 1534-1583.
Schiphof-Godart L, van der Wiel E, Ten Hacken N, et al. Development of a tool to recognize small airways dysfunction in asthma (SADT). Health Qual Life Outcomes 2014; 12: 155.
Ostridge K, Gove K, Kirby M, et al. Using DPM CT analysis to assess the contribution of small airways disease in COPD. Eur Respir J 2018; 52: Suppl. 62, OA3795.
Tanabe N, Sato A, Mizutani T, et al. Protease anti-protease imbalance and small airways disease in COPD. Eur Respir J 2018; 52: Suppl. 62, PA4256.
Biddiscombe M, Saleem A, Meah S, et al. Efficacy of the device in targeting tiotropium to the small airways in COPD. Eur Respir J 2018; 52: Suppl. 62, PA1017.
Bonini M, Usmani OS. Novel methods for device and adherence monitoring in asthma. Curr Opin Pulm Med 2018; 24: 63-69.
Honkoop PJ, Simpson A, Bonini M, et al. MyAirCoach: the use of home-monitoring and mHealth systems to predict deterioration in asthma control and the occurrence of asthma exacerbations: study protocol of an observational study. BMJ Open 2017; 7: e013935.
Simpson AJ, Honkoop PJ, Kennington E, et al. Perspectives of patients and healthcare professionals on mHealth for asthma self-management. Eur Respir J 2017; 49: 1601966.
Morice AH, Fontana GA, Belvisi MG, et al. ERS guidelines on the assessment of cough. Eur Respir J 2007; 29:1256-1276.
French CL, Irwin RS, Curley FJ, et al. Impact of chronic cough on quality of life. Arch Intern Med 1998; 158:1657-1661.
Canning BJ, Mori N, Mazzone SB. Vagal afferent nerves regulating the cough reflex. Respir Physiol Neurobiol 2006; 152: 223-242.
Blum E, Drake M, Fryer A, et al. Airway sensory innervation is increased in chronic cough. Eur Respir J 2018; 52: Suppl. 62, OA3565.
Nijboer S, De Groot AP, VohiDalova E, et al. Allergen-induced BDNF expression and neuronal remodelling contributes to airway hyperresponsiveness. Eur Respir J 2018; 52: Suppl. 62, PA5262.
Chen X, Bonvini SJ, Dubuis E, et al. Characterisation of TRPA1 activation on sensory nerves. Eur Respir J 2018; 52: Suppl. 62, PA5263.
Wortley MA, Bonvini SJ, Flajolet PLM, et al. The anti-tussive effects of an inhaled LABA are maintained after chronic treatment. Eur Respir J 2018; 52: Suppl. 62, PA5261.
Abdulqawi R, Dockry R, Holt K, et al. P2X3 receptor antagonist (AF-219) in refractory chronic cough:a randomised, double-blind, placebo controlled phase 2 study. Lancet 2015; 286: 244-245.
Smith JA, McGarvey LP, Morice AH, et al. The effect of baseline factors on treatment response with MK-7624, a P2X3 antagonist, in refractory chronic cough. Eur Respir J 2018; 52: Suppl. 62, PA811.
Birring SS, Muccino DR, Morice AH, et al. Patient characteristics and triggers eliciting chronic cough. Eur Respir J 2018; 52: Suppl. 62, PA820.